Stay updated on EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial
Sign up to get notified when there's something new on the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page.

Latest updates to the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page
- CheckyesterdayChange DetectedThe page now indicates that the study has increased to 12 locations, including a specific site in Lyon, France, and has updated the relevant dates.SummaryDifference0.7%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated to reflect changes in the study protocol for the Phase III trial of alpelisib in combination with trastuzumab and pertuzumab for HER2-positive advanced breast cancer, including the confirmation of the recommended phase 3 dose and the unblinding of participants in Part 2 of the study.SummaryDifference26%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 7, 2025.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EPIK-B2 Study: Alpelisib with Trastuzumab & Pertuzumab Clinical Trial page.